CA2606378A1 - Fcrn antibodies and uses thereof - Google Patents

Fcrn antibodies and uses thereof Download PDF

Info

Publication number
CA2606378A1
CA2606378A1 CA002606378A CA2606378A CA2606378A1 CA 2606378 A1 CA2606378 A1 CA 2606378A1 CA 002606378 A CA002606378 A CA 002606378A CA 2606378 A CA2606378 A CA 2606378A CA 2606378 A1 CA2606378 A1 CA 2606378A1
Authority
CA
Canada
Prior art keywords
human
antibody
fcrn
binding portion
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002606378A
Other languages
English (en)
French (fr)
Inventor
Derry Charles Roopenian
Shreeram Akilesh
Gregory James Christianson
Stefka Petkova
Thomas J. Sproule, Jr.
Emanuele Pesavento
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2606378A1 publication Critical patent/CA2606378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002606378A 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof Abandoned CA2606378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67641205P 2005-04-29 2005-04-29
US60/676,412 2005-04-29
PCT/US2006/014182 WO2006118772A2 (en) 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA2606378A1 true CA2606378A1 (en) 2006-11-09

Family

ID=37105335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002606378A Abandoned CA2606378A1 (en) 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof

Country Status (5)

Country Link
US (1) US20100266530A1 (OSRAM)
EP (1) EP1879920A2 (OSRAM)
JP (1) JP2008538919A (OSRAM)
CA (1) CA2606378A1 (OSRAM)
WO (1) WO2006118772A2 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524664A (ja) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
EP2195028A2 (en) 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
AU2015200004B2 (en) * 2008-04-25 2017-02-16 Bioverativ Therapeutics Inc. Antibodies against fcrn and use thereof
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
US8232067B2 (en) 2009-05-29 2012-07-31 Brigham & Women's Hospital, Inc. Disrupting FCRN-albumin interactions
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
EP2970406B1 (en) 2013-03-15 2017-12-13 Affibody AB New polypeptides
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
JP6620094B2 (ja) * 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
CA2934644C (en) 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
EP3804745A1 (en) * 2014-04-25 2021-04-14 The Brigham and Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
EP3134733B1 (en) * 2014-04-25 2020-10-14 The Brigham and Women's Hospital, Inc. Assay and method for treating subjects with immune-mediated diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
NZ726089A (en) * 2014-04-30 2017-12-22 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
HK1251483A1 (zh) * 2015-05-12 2019-02-01 Synt免疫公司 人源化亲和力成熟的抗fcrn抗体
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
JP2023531451A (ja) * 2020-06-17 2023-07-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子療法患者の治療のための組成物及び方法
EP4384548A4 (en) * 2021-08-13 2024-11-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND THEIR USES
CN119013290A (zh) * 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
JP2025522251A (ja) 2022-05-30 2025-07-15 ハナル バイオファーマ カンパニーリミテッド 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
EP1660128A4 (en) * 2003-08-08 2009-01-21 Univ New York State Res Found ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions

Also Published As

Publication number Publication date
US20100266530A1 (en) 2010-10-21
EP1879920A2 (en) 2008-01-23
WO2006118772A2 (en) 2006-11-09
WO2006118772A9 (en) 2008-03-06
JP2008538919A (ja) 2008-11-13
WO2006118772A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US20100266530A1 (en) FcRN ANTIBODIES AND USES THEREOF
JP7819160B2 (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
CA3092456C (en) Anti-tigit antibody and use thereof
CN109789201B (zh) 抗人vista抗体及其用途
TWI748984B (zh) Bcma及cd3雙特異性t細胞嚙合抗體構築體
ES3040289T3 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
ES2846748T3 (es) Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma
US9416169B2 (en) Humanized monoclonal antibodies and methods of use
EP3981790A1 (en) Binding molecule specific for cd73 and use of binding molecule
US20220235142A1 (en) Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof
KR20170135860A (ko) 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
CN106163556A (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
JP2018529317A (ja) メソテリン及びｃｄ３に結合する二重特異性抗体構築物
CA3143995A1 (en) Anti-tigit antibodies
CN108026170A (zh) 抗cd71抗体、可活化抗cd71抗体及其使用方法
CN107531758A (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN101720232A (zh) 具有修饰的效应器功能的fc受体结合型多肽
US11597763B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
CA2875451A1 (en) Antibody against transporter and use thereof
CN114853890A (zh) 一种prlr抗原结合蛋白及其制备方法和应用
RU2786434C2 (ru) Антитело к tigit и его использование
WO2024259378A1 (en) T cell engager masking molecules
US20070224196A1 (en) Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon
BR112020013018A2 (pt) construto de anticorpo biespecífico direcionado para muc17 e cd3
NZ736142B2 (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140124